Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis | Zendy

Nezar Boreak | Zendy

Open Access

Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis

Author(s) -

Nezar Boreak

Publication year - 2021

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2021/6631848

Subject(s) - oral submucous fibrosis , fibrosis , transforming growth factor , transforming growth factor beta , cancer research , downregulation and upregulation , medicine , transforming growth factor, beta 3 , pathology , growth factor , chemistry , tgf alpha , receptor , gene , biochemistry

Oral submucous fibrosis (OSMF) is considered a premalignant condition characterized by aggressive fibrosis of the submucosal tissues of the oral cavity reflecting its malignant transformation potential. Activation of transforming growth factor beta (TGF- β ) signaling has been reported to lead increased collagen production and fibrosis. Recently, significant upregulation of TGF- β 1 has been reported in OSMF as compared to normal tissues. Therefore, inhibition of the TGF- β 1 may pave for the development of therapeutics of OSMF. Based on the structure-assisted drug designing, we found “silmitasertib” as potent inhibitor of TGF- β 1. We suggest that this molecule can be validated and implemented for the treatment of OSMF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research